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Folic acid insufficiency has long been related to the occurrence of various diseases. However, the loss 
of integrity of folic acid has led to the investigation of strategies to improve the vitamin stability and 
controlled release. Porous silicon nanoparticle is an attractive inorganic material for drug delivery 
applications due to its biocompatibility and tunable degradation behavior. The aim of this work is to 
produce porous silicon nanoparticles with suitable dimensions for loading folic acid. Porous silicon 
was fabricated by anodic electrochemical etching in a Teflon cell containing a 1:4 (v/v) solution of 
49% aqueous HF in ethanol. Pores between 15 and 20 nm in diameter were obtained and the highly 
degradable porous silicon was stabilized to SiO2 structures by thermal oxidation. Folic acid was loaded 
into these structures by simple adsorption and the release was examined by UV absorption 
spectroscopy. The surface morphology of porous silicon delivery device in each stage of the 
fabrication was characterized by FE-SEM, X-ray spectrometer, FTIR, and XRD and the drug loading 
confirmed based on the comparison with pure folic acid spectra. pSi nanoparticles showed optimal 
folic acid delivery capabilities (60 % released after 6 h) and due to its simple fabrication method and 
its intrinsic optical properties have the potential to be used as a diagnostic and therapeutic point of care 
tool. 
 
 
Keywords: Folic acid, Porous silicon, Drug delivery 
 
 
 
1. INTRODUCTION 
Folic acid is a water-soluble molecule from the B complex of vitamins. The natural occurring 
form of folic acid, folate, is not synthesized in humans and it is typically obtained through 
consumption of green vegetables or dietary supplements [1]. Folic acid coenzymes facilitate the 
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transfer of carbon units, which aid the biosynthesis of purines and pyrimidines, crucial molecules in 
the synthesis and repair of DNA [2]. Folic acid is known to be essential for the growth and division of 
cells, which is particularly important during pregnancy and infancy [3]. The insufficiency of folic acid 
has long been known to be related to certain diseases such as neural tube defects in fetus [4] and 
megaloblastic anaemia [5]. Other ailments associated with folic acid shortage range from nervous 
system disturbances [6], for example Alzheimer disease [7], [8], to cardiovascular disorders [9], and 
cancer [10], [11]. The latter has recently raised controversy, since high levels of folate have been 
reported to have negative effects in patients with high risk of cancer [12], [13]. On the other hand, the 
loss of integrity of folic acid, which undergoes degradation when exposed to light, acid or alkaline 
medium and oxygen atmosphere, has led to the investigation of strategies for improvement of the 
vitamin stability. Furthermore, since folic acid is easily excreted from the human body, vitamin 
deficiency usually occurs [14]. 
The development of materials for the delivery of folic acid either alone or in combination with 
other drugs for pharmaceutical applications has received great attention. A particular case is the 
loading of folic acid with anticancer drugs such as doxorubicin [15], [16], [17]. Cancer cells contain 
greater number of folate receptors compared with normal cells, hence folic acid has been used as a 
targeting ligand in these anticancer drug delivery systems [18]. Silica modified gold nanorods [19], 
[20] and folic acid conjugated gold nanoparticles [21] and magnetic nanoparticles [22], [23] have also 
been investigated for controlled delivery of folic acid.   
Since the discovery of its intrinsic visible photo- and electroluminescence properties, 
nanostructure porous silicon (pSi) has been extensively used in a wide range of applications such as 
optical and biosensing devices [24], [25]. pSi nanoparticles for drug delivery system can be easily 
fabricated by electrochemical etching of silicon wafer in an electrochemical solution. The porosity, 
tunable pore size and the high specific surface area (200–800 m2/g) are responsible for the optical 
properties of pSi [26]. These characteristics also provide stability in physiological fluids and 
biocompatibility due to similar silicon levels in blood compared with other physiological elements 
such as iron, zinc and copper [27]. Furthermore, it degrades into silicic acid, which can be excreted 
through the urine. This confers silicon its extraordinary biodegradable and non-toxic properties. These 
characteristics have imparted a significant advantage to pSi compared with other materials, allowing 
the expansion of pSi to biomedical applications such as radiotherapy [28], tissue engineering [29] and 
drug delivery devices [30], [31], [32]. pSi nanoparticles are still under investigation. Maniya et al. 
recently studied the effect of current density and etching time on pore size, porosity, and thickness of 
the pSi nanoparticles and its application as a carrier for different type of drugs [33].  
The development of pSi nanoparticles as drug delivery devices are focused on a particular drug 
in each case, such as doxorubicin, dexamethasone [34], antipyrine, ibuprofen, griseofulvin, ranitidine 
and furosemide [35], peptides [36] and anti-cancer drugs such as daunorubicin [37] and mitoxantrone 
dihydrochloride [38]. To our knowledge folic acid has never been loaded in pSi nanoparticles, but in 
other types of silicon materials such as silica [39], [15], [17] or together with anticancer drugs [16] and 
magnetic nanoparticles (Fe2O3-SiO2) [23]. Hence, we aim to investigate the use of pSi nanoparticles as 
potential folic acid carriers. For this, the fabricated pSi was first characterized by Field Emission 
Scanning Electron Microscopy (FE-SEM) and the chemical compositions of the samples were 
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determined by an Energy Dispersive X-ray (EDX) Spectrometer, X-ray diffraction (XRD), (FTIR) 
Fourier transform infra red spectroscopy. The release of the drug was monitored by UV absorption 
spectroscopy. 
 
 
 
2. MATERIALS AND METHODS 
2.1. Chemicals and Solutions 
All chemicals, hydrofluoric acid 49%, ethanol alcohol, ammonium hydroxide, hydrochloric 
acid, hydrogen peroxide and phosphate buffer saline (PBS) were purchased from Sigma Aldrich 
(Malaysia). The n-type Si wafers (single crystalline n-type, 0.008-0.018 Ω resistivity and <100> 
orientation) were purchased from Siltronix SAS (Archamps, France). 
 
2.2. Preparation of pSi nanoparticles 
Porous silicon samples were prepared from single crystalline n-type Si wafers. These were first 
cleaned in a solution of 1:1:5 NH4OH:H2O2:H2O for 10 min at 70-80 ºC, then in 1:50 HF:H2O for 15 
sec and finally in 1:1:6 HCL:H2O2:H2O for 10 min at 70-80 ºC. Porous silicon was fabricated by 
anodic electrochemical etching in a Teflon cell containing a 1:4 (v/v) solution of 49% aqueous HF in 
ethanol. The current density was held at 20 mA/cm
2
 for 30 min and the sample was illuminated with an 
incandescent white light of 40 W. Lift-off methods were utilized for removing the porous layer from Si 
substrate with application of current density of 250 mA/cm
2
 for 30 sec, and then porous layer 
converted into microparticles by using ultrasonic fracture.  
Chemical oxidation of pSi films was carried out by thermal oxidation. The pSi nanoparticles 
were heated at 800 ºC in the oven for 1 hour and then the sample was allowed to slowly cool down to 
room temperature.  
 
2.3. Loading Folic Acid on the pSi Nanoparticles 
The folic acid solution consisted of (10 mg/ml) in sodium hydroxide. The particles were soaked 
in drug solution for 3 hours and this was stirred at intervals to allow homogeneity. After that the 
solvent was allowed to evaporate. The particles were briefly rinsed with deionized water to remove 
any excess drug remaining on the surface that had not infiltrated the pores.  
 
2.4. Characterization 
Following each of the steps during the fabrication of pSi as a drug carrier (i.e: electrochemical 
etching, oxidation and loading) the samples were characterized by Field Emission-Scanning Electron 
Microscopy (FE-SEM) JSM-6701F to observe the surface of porous silicon and Energy Dispersive X-
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ray Spectroscopy EDX to provide elemental analysis. Other techniques such as X-ray diffraction 
(XRD) and FTIR were used to investigate the pSi fabrication, modification and folic acid loading 
process. 
 
 
 
3. RESULTS AND DISCUSSION 
3.1. Fabrication of pSi by Electrochemical Etching  
In this work we have studied pSi nanoparticles prepared by electrochemical etching as a drug 
carrier device for loading folic acid. Firstly, we studied the porosity characterized by FE-SEM as 
shown in (Fig. 1). 
 
 
 
Figure 1. (a) FESEM image of porous silicon (b) pore size distribution histogram (c) FESEM image of 
porous silicon microparticles after fracturing by sonication. 
 
Fig. 1a shows the FE-SEM image carried out to determine the optimum morphology of the pSi 
formed. The pores diameter, calculated by ImageJ software, ranged between 5 to 50 nm with an 
average pore distribution between 15 to 20 nm as shown in the histogram graph (Fig. 1b). The pores 
appear uniformly distributed throughout the structures suggesting an appropriated fabrication method. 
Furthermore, the pore size agrees with the optimum pore size for loading low molecular weight drugs 
[40], [41]. Figure 1c shows the FE-SEM image of Si nanoparticles after fracture by sonication. The 
image reveals uniform microparticles, with an average size of 40 ± 5 µm and high specific surface area 
(460 m
2
/g), calculated with nitrogen gas according to Brunauer–Emmett–Teller (BET) theory [42], 
which allows the loading of folic acid. 
 
3.2. pSi Surface Modification and Drug Loading Process 
Following the fabrication of pSi nanoparticles the surface was modified by thermal oxidation in 
the oven at 800 ºC for 60 min. The oxidation process increases the stability of the material in aqueous 
solvents and decreases the hydrophobicity of silicon [43]. EDX was used to confirm the elemental 
analysis of the pSi samples at various steps of the fabrication process (Fig. 2). A single peak 
corresponding to Si was observed in the elemental analysis of fresh pSi (Si wafer after etching) (Fig. 
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2a). Following thermal modification, oxygen atomic percentages were perceived (Fig. 2b), confirming 
the incorporation of oxygen on the surface of pSi during the oxidation process. EDX for folic acid was 
performed as a reference, confirming its chemical structure (C19H19N7O6) (Fig. 2c). Hence, the 
existence of carbon and nitrogen atomic percentages in Fig. 2d was attributed to the loading of folic 
acid into pSi. The elemental analysis of folic acid loaded in oxidized pSi (Fig. 2e) showed a lower 
loading rate compared with freshly prepared pSi (Fig. 2d), due to the shrinking of the pores during the 
oxidation process. 
 
 
Figure 2. EDX spectrum of a) freshly prepared pSi nanoparticles, b) oxidized pSi nanoparticles, c) 
pure folic acid, d) folic acid loaded in freshly prepared pSi nanoparticles and e) folic acid 
loaded in oxidized pSi nanoparticles. 
 
3.3. X-ray diffraction (XRD) Analysis 
X-ray diffraction analysis of pSi nanoparticles was performed with a Bruker D8 Advance 
diffractometer (XRD). Fig. 3 presents the XRD data recorded in the 2θ range (0-70°) of pSi 
nanoparticles, pSi after thermal surface modification and pSi after loading of folic acid. The XRD data 
of pSi nanoparticle showed a sharp peak at 2θ = 69° corresponding to the (400) plane reflection of Si 
(Fig. 3a). The XRD pattern of oxidized porous silicon crystal structure is observed in Fig. 3b. During 
thermal surface modification at 800°C the Si is oxidized to SiO2, resulting in a new crystalline 
structure (SiO2 crystalline structure, JCPDS 39-1425 [44]) and a reduction of the Si pores size. This 
reduction of pores size is observed in the reduction of intensity peak in the XRD data [45]. The 
diffraction peaks of folic acid are reported to be at 2θ between 10° and 30° [46] with a centered peak at 
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~ 22° [47]. This folic acid peak at 2θ ~ 22° and the pSi peak at 2θ ~ 69° are observed in the XRD data 
in Fig 3c confirming the successful loading of folic acid into pSi nanoparticles. 
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Figure 3. XRD pattern of a) freshly prepared pSi, b) oxidized pSi at 800 °C and c) pSi loading with 
folic acid. 
 
3.4. FTIR Spectroscopy 
Fourier transform infrared (FTIR) spectroscopy was used to investigate the chemical bonds of 
the pSi nanoparticles at different stages of the fabrication procedure over the wave number range 500-
4000 cm
-1
. Before loading the folic acid, the FTIR spectrum of the freshly etched pSi displays bands 
characteristic of surface hydride species (Fig. 4a). This spectrum shows a number of absorbance bands, 
the band at 2100 cm
-1 
is attributed to the stretching mode of SiH [34].The Si-O-Si absorbance observed 
at 1069 cm
-1 
is due to the oxidation of the sample while handling the preparation pallet for FTIR 
analysis. The absorbance observed at 621 cm
-1 
and 872 cm
-1
 are attributed to different SiHx 
deformation modes [48]. Fig. 4b shows the spectrum after oxidation of pSi at 800 °C. Here the Si-O-Si 
absorbance at 1069 cm
-1
, due to the oxidation of the sample and new vibrational modes at 3412cm
-1 
attributed to Si-OH, are observed [49]. Folic acid was loaded into the fabricated pSi nanoparticles 
following surface modification. The FTIR spectrum of this sample (Fig. 4c) shows absorption at 
different wave numbers, 1637.01 cm
-1 
for the carbonyl group, 1384.38 cm
-1 
(C=C), 1477cm
-1
 (phenyl, 
pterin ring) and 3442.13 cm
-1 
due to hydroxyl stretching bonds and NH group [50]. Folic acid is 
composed of p-amino benzoic acid, glutamic acid and a hetero-bicyclic pteridine [50] as observed in 
its FTIR spectrum (Fig. 4d). Hence, the successful loading of folic acid can be confirmed by the 
comparison of the infrared spectrum of nanoparticles with the infrared spectrum of pure folic acid. 
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Figure 4. Fourier transform infrared (FTIR) spectra of different pSi nanoparticles, showing a) freshly 
etched pSi, b) the oxidized pSi nanoparticles treated by thermal oxidation at 800 °C, c) 
oxidized pSi after drug loading displaying the characteristic vibrational bands of folic acid and 
d) reference spectrum of folic acid. 
 
3.5. In vitro Release  
Pharmacological compounds of folic acid are prepared in alkaline media due to its higher 
stability and solubility. Typically folic acid tablets are administered orally and the active principle is 
absorbed through the intestinal walls. However, the acidic environment of the stomach degrades the 
active principle of the drug before this can be absorbed through the intestines [51]. Hence, slightly 
basic pH media are commonly used to monitor the release of folic acid from the carrier device. 
 
Since the rate of release of the drug is limited by the degradation of the device itself, the release 
of folic acid from the pSi nanoparticles was monitored as a function of time. UV absorption 
spectroscopy was used to monitor the drug release at pH 7.4 in PBS solution at intervals of 
approximately 40 min during 6 h. The solution absorbance band at 300 nm increased with time as the 
folic acid is released from the oxidized porous silicon nanoparticles as observed in Fig. 5. 
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Figure 5. Percentage of folic acid released in PBS as a function of time monitoring by UV absorption 
spectroscopy (pH = 7.4 and λ = 300 nm). 
 
Table 1.  Percentage of folic acid released in different drug delivery devices. 
 
Devices Released % Time pH of Solution Publication 
Ethyl Cellulose 
Microcapsules 
32% and 70% 1 and 6 h, 
respectively 
pH = 7.4  [52] 
Commercial folic acid 
tablet 
60% and 90% 1 and 5 h, 
respectively 
pH = 7.4 [52] 
Sodium alginate-pectin-
poly(ethylene oxide) 
electrospun fibers 
90-100% 2h pH = 7.8 [53] 
Poly(DL-lactide-co-
glycolide) Nanospheres 
20 % and > 82% 12 and 30 days, 
respectively 
pH = 7.4 [54] 
Polyion complex 
micelles (PICMs) 
60 and 90-100% 2 and 10 h, 
respectively 
pH = 7.4  [55] 
Porous silicon 
nanoparticles 
~10 % and ~60 % 1 and 5 ½ h, 
respectively 
pH = 7.4 (PBS) this work 
 
Results showed that folic acid was released within one hour from immersion in the PBS and 
continue to increase with time. After 330 min 58.87% of folic acid was released from the stable pSi 
surface. This presents longer released times compared with the commercial folic acid tablets, which at 
pH of 7.4 showed a released of 60% and 90% after 1 and 5 h, respectively [52]. Other drug carriers 
produced for the delivery of folic acid showed a range of percentage released and time depending on 
the material used (Table 1). These differences may be useful for different applications, where a carrier 
might be chosen depending on the amount of drug released required. Nevertheless, pSi nanoparticles 
are relatively simple to fabricate and provide an excellent release rate, which depends on the 
hydrolysis reaction of pSi with water. Silicon presents a low solubility in water, which counts for its 
reversibility, however, silicon solubility increases with the pH of the solution as shown in [16]. 
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Anyhow, the solubility of pSi can be further controlled with polymer coatings. In addition pSi presents 
outstanding optical and biocompatibility properties, allowing the combination of imaging, biosensing 
and drug delivery capabilities to create ‘close-loop’ systems for the improvement of diagnostic and 
therapeutic healthcare. 
 
 
 
4. CONCLUSION 
The feasibility of pSi as folic acid delivery device was investigated in this study. The device 
was fabricated by electrochemical etching of silicon wafer, resulting in porous microparticles, which 
were further stabilized by thermal oxidation. Folic acid was successfully loaded in the nanoporous 
silicon and confirmed by EDX, XRD and FTIR based on the comparison with pure folic acid. The 
release of folic acid was monitored by UV absorption spectroscopy showing a 10 % and 60 % release 
after 30 min and 6 h, respectively. This corresponds with a slower degradation rate compared with 
commercial folic acid tablets and agrees with other drug delivery materials. Overall, pSi nanoparticles 
present optimal folic acid delivery capabilities and together with its intrinsic optical properties and 
biocompatibility have the potential to be used as wearable devices for point of care, where the 
diagnosis triggers the drug release.  
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